Overview

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunologic parameters: - Increase in natural killer (NK) cell activity. - Increase in total T-cells (OKT-11). - Increases in absolute number and percentages of T-helper cells (OKT-4).

Phase:

N/A

Details

Lead Sponsor:

Newport Pharmaceuticals International

Treatments:

Inosine Pranobex